SAN DIEGO, April 21, 2016 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases, today announced presentations for both of its clinical stage oncology product candidates, TRC105 and TRC102, at the upcoming American Society of Clinical Oncology (ASCO) annual meeting to be held June 3-7, 2016, in Chicago, Illinois.
The following is a summary of the three presentations that will be given at ASCO:
|Poster Discussion Presentation|
|Title:||A Phase 1b/Phase 2a study of TRC105 in combination with pazopanib in patients with advanced soft tissue sarcoma (Abstract #11016)|
|Presenter:||Steven Attia, DO, Assistant Professor of Oncology, Mayo Clinic-Jacksonville|
|Location:||S Hall A, Poster Board 142 (poster display)|
|S406 (poster discussion)|
|Date/Time:||Monday, June 6, 2016, 8:00 AM – 11:30 AM, Central time (poster display)|
|Monday, June 6, 2016, 3:00 PM – 4:15 PM, Central time (poster discussion)|
|General Poster Presentations|
|Title:||A Phase 2 trial of TRC105 with bevacizumab for bevacizumab refractory glioblastoma (Abstract #2035)|
|Presenter:||Manmeet Ahluwalia, MD, FACP, Director, Brain Metastasis Research Program, Burkhardt Brain Tumor NeuroOncology Center, Cleveland Clinic|
|Location:||S Hall A, Poster Board 224|
|Date/Time:||Saturday, June 4, 2016, 1:00 PM – 4:30 PM, Central time|
|Title:||A Phase 1 trial of TRC102 (methoxyamine HCl) with temozolomide in patients with solid tumors and lymphomas (Abstract #2556)|
|Presenter:||Robert S. Meehan, MD, National Cancer Institute|
|Location:||S Hall A, Poster Board 256|
|Date/Time:||Sunday, June 5, 2016, 8:00 AM – 11:30 AM, Central time|
TRC105 is a novel, clinical stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis, the process of new blood vessel formation. TRC105 is currently being studied in multiple Phase 2 clinical trials sponsored by TRACON or the National Cancer Institute for the treatment of solid tumor types in combination with VEGF inhibitors. The ophthalmic formulation of TRC105, DE-122, is currently in a Phase 1/2 trial for patients with wet AMD. TRC205, a second generation antibody to endoglin, is undergoing preclinical testing in models of fibrosis. For more information about the clinical trials, please visit TRACON’s website at http://www.traconpharma.com/clinical_trials.php.
TRC102 (methoxyamine) is a novel, clinical-stage small molecule inhibitor of the DNA base excision repair pathway, which is a pathway that causes resistance to alkylating and antimetabolite chemotherapeutics. TRC102 is currently being studied in multiple Phase 1 and Phase 2 clinical trials sponsored by the National Cancer Institute or Case Comprehensive Cancer Center. For more information about the clinical trials, please visit TRACON’s website at http://www.traconpharma.com/clinical_trials.php.
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Source:TRACON Pharmaceuticals, Inc.